9.
Loss per Share
Basic
and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period.
Schedule of Computation of Basic and Diluted Net Loss Per Share
| | |
| | |
| | |
| | |
| |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| Basic and diluted net loss per common share: | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Numerator: | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (1,248,237 | ) | |
$ | (1,042,572 | ) | |
$ | (2,059,028 | ) | |
$ | (7,148,459 | ) |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares outstanding | |
| 16,193,404 | | |
| 11,328,122 | | |
| 13,906,860 | | |
| 7,137,017 | |
| Net loss per share of common stock—basic and diluted | |
$ | (0.08 | ) | |
$ | (0.09 | ) | |
$ | (0.15 | ) | |
$ | (1.00 | ) |
HEPION
PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes
to Condensed Consolidated Financial Statements
(Unaudited)
The
following outstanding securities at June 30, 2026 and 2025 have been excluded from the computation of basic and diluted weighted shares
outstanding, as they would have been anti-dilutive due to net loss:
Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding
| | |
2026 | | |
2025 | |
| | |
Six Months Ended
June 30, | |
| | |
2026 | | |
2025 | |
| Common shares issuable for: | |
| | | |
| | |
| Series A preferred stock | |
| 3 | | |
| 3 | |
| Series C preferred stock | |
| 16 | | |
| 16 | |
| Stock options | |
| 2,021 | | |
| 7,813 | |
| Warrants – liability classified | |
| 3,477,775 | | |
| 3,492,481 | |
| Warrants – equity classified | |
| — | | |
| 1,795 | |
| Total | |
| 3,479,815 | | |
| 3,502,108 | |
The
strike price for the equity classified warrants was $2,500 each and expired in February 2026.
|